Skip to main content
All Posts By

Redpin Therapeutics

Redpin Therapeutics secures initial closing of $15.5 million in Series A financing

By Press Release
4BIO Capital and Arkin Bio Ventures lead first close joined by Takeda Ventures and existing investors Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced it has secured $15.5 million in the initial closing of its Series A financing round. The round was led by 4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, and Arkin Bio Ventures, the investment arm of Arkin Holdings, which specializes in pharmaceutical and biotechnology innovations that have imminent breakthrough potential, and joined by new investor Takeda...
Read More

New Paper in Science Reports Discovery of Ultrapotent Chemogenetic Approach that Forms Scientific Foundation for Redpin Therapeutics’ Technology

By Press Release
Engineered receptors and ultrapotent, FDA-approved agonists enable clinical applications of chemogenetics Novel ion channel-based platform allows targeted cell activation or silencing controlled by low doses of the anti-smoking drug varenicline Redpin leveraging platform to advance pipeline of targeted cell therapies for currently intractable diseases of the nervous system Redpin Therapeutics, Inc., a gene therapy company leveraging its proprietary chemogenetics platform to advance targeted cell therapies that address currently intractable diseases of the nervous system, today announced the publication of a new paper in the journal Science describing the company’s foundational science. The paper, appearing online today, documents the discovery and...
Read More

Lilly Neuroscience Veteran David Bleakman Joins Redpin Therapeutics as Chief Scientific Officer

By Press Release
Company advancing novel platform technologies to enable non-invasive, targeted regulation of neuronal cell activity Aiming to address currently intractable neurologic and psychiatric diseases Redpin Therapeutics today announced the appointment of David Bleakman, PhD, as its Chief Scientific Officer (CSO). Founded in 2017, Redpin is advancing novel platform technologies that enable the non-invasive, targeted regulation of neuronal cell activity in the brain to address crucial unmet needs for patients with severe neurological disorders. Redpin’s co-founders include Jeffrey Friedman, MD, PhD (Rockefeller University/Howard Hughes Medical Institute); Scott Sternson, PhD (Howard Hughes Medical Institute, Janelia Research Campus); Michael Kaplitt, MD, PhD (Weill Cornell...
Read More